Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NET1
REST API REST API
Homo sapiens
NET1 is differentially expressed in 314 experiments: 146 organism parts: placenta, trachea, ... (144 more);, 199 disease states: normal, glioblastoma, ... (197 more);, 108 cell types 452 cell lines 50 compound treatments and 80 other conditions.
Synonyms ARHGEF8, NET1A
Orthologs ROM1 (Saccharomyces cerevisiae)   ENSCING00000007425 (Ciona intestinalis)   ROM2 (Saccharomyces cerevisiae)   Q5ZJM0_CHICK (Gallus gallus)   Q3ZC77_BOVIN (Bos taurus)   Net1 (Mus musculus)   net1 (Danio rerio)   Net1 (Rattus norvegicus)   net1 (Xenopus laevis)   NET1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, intracellular, positive regulation of apoptosis, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, small GTPase mediated signal transduction, nucleus, regulation of small GTPase mediated signal transduction, Rho guanyl-nucleotide exchange factor activity, regulation of cell growth, signal transduction, cellular response to hydrogen peroxide, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, intracellular signal transduction, positive regulation of Rho GTPase activity, cellular response to ionizing radiation
InterPro Term Pleckstrin_homology, DH-domain
UniProt Accession Q5SQI5, Q5SQI7, Q5SQI6, B4E1Y1, Q7Z628, F5GZS5
Search EB-eye ENSG00000173848
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (37 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
AGS
2
E-MTAB-37, E-GEOD-15460
HCC2157
2
E-MTAB-37, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
446 more value(s).


Cell type

studied in E-MEXP-750, E-GEOD-20677, E-TABM-34, E-GEOD-2822, E-GEOD-21750, ... (54 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-22373, E-GEOD-360, E-GEOD-5099
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
n/a
1
E-MTAB-24
type I helper T cell
1
E-GEOD-3982
type II helper T cell
1
E-GEOD-3982
CD19+ B cell
1
E-MEXP-1600
102 more value(s).


Disease state

studied in E-GEOD-3307, E-TABM-15, E-GEOD-12254, E-GEOD-16363, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
glioblastoma
1
5
E-GEOD-6014, E-MTAB-37, E-GEOD-4290, E-GEOD-4412, E-MTAB-62, ... (6 experiments)
adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-1331
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
193 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, E-MEXP-941, ... (32 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
galectin-1
1
E-GEOD-4984
CNOT7+CNOT8
1
E-MEXP-2218
control - IL-1b
1
E-GEOD-7216
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
44 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138, E-GEOD-1751, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, E-TABM-868, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-1956, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-6927, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.437 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM